However, given the well-known activation of the IL-23/IL-17 pathway in autoimmune chronic diseases such as Crohn’s or psoriasis [47,48], further studies will be needed to determine whether a local administration of this ‘cytokine mix’ might be desirable in more chronic lung conditions, such as cystic fibrosis, where lung pathogens such as P.a are also prominent. The gene discussed is IL17A; the disease is psoriasis.